Summary
For Year 2026-27, Zydus Lifesciences reports the following shareholding: Total Promoters at 75%, Mutual Fund at 4.88%, Insurance at 6.11%, Foreign Institutional Investors at 6.95%, Domestic Institutional Investors at 0.21%, and Retail at 6.86%. This breakdown provides a quick snapshot of ownership distribution for Zydus Lifesciences in 2026-27.
Zydus Lifesciences FAQs
As of 04-2026, the promoter shareholding in Zydus Lifesciences stands at 75% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Zydus Lifesciences is 6.95% and 0.21% respectively.
The retail shareholding of the Zydus Lifesciences is 6.86%.
Changes in shareholding patterns of Zydus Lifesciences can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Zydus Lifesciences are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Zydus Lifesciences Associated Pages
